» Articles » PMID: 32192530

Chemical-defined Medium Supporting the Expansion of Human Mesenchymal Stem Cells

Overview
Publisher Biomed Central
Date 2020 Mar 21
PMID 32192530
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Mesenchymal stem cells (MSCs) have been intensively investigated as to their therapeutic potentials. However, the full chemical-defined medium supporting the isolation and expansion of human MSCs has not been developed yet.

Materials And Methods: Here, we developed the full chemical-defined medium, NBVbe medium, via RNA sequencing, bioinformatic analysis, and growth factor screening.

Results: The NBVbe medium contains N2B27 medium with the BSA (bovine serum albumin) replaced by the recombinant human albumin, bFGF (basic fibroblast growth factor), vitamin C, and EGF (epidermal growth factor). The NBVbe medium could support the isolation and expansion of human MSCs from the umbilical cords.

Conclusions: The full chemical-defined medium supporting the isolation and expansion of human MSCs has been developed. This would be helpful for further optimization of the MSC medium, their clinical applications, and molecular characterization.

Citing Articles

High throughput morphological screening identifies chemically defined media for mesenchymal stromal cells that enhances proliferation and supports maintenance of immunomodulatory function.

Spoerer T, Larey A, Asigri W, Daga K, Marklein R Stem Cell Res Ther. 2025; 16(1):125.

PMID: 40055728 PMC: 11889916. DOI: 10.1186/s13287-025-04206-8.


Enhanced myofibroblast differentiation of eMSCs in intrauterine adhesions.

Song J, Li M, Tao Y, Li Y, Mai C, Zhang J Stem Cell Res Ther. 2025; 16(1):35.

PMID: 39901307 PMC: 11792338. DOI: 10.1186/s13287-025-04183-y.


Induction of periodontal ligament-derived mesenchymal stromal cell-like cells from human induced pluripotent stem cells.

Wang J, Morita K, Iwata T Regen Ther. 2024; 26:432-441.

PMID: 39045575 PMC: 11263952. DOI: 10.1016/j.reth.2024.05.005.


Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations.

Chen S, Liang B, Xu J J Transl Med. 2024; 22(1):459.

PMID: 38750573 PMC: 11094970. DOI: 10.1186/s12967-024-05294-5.


Improved therapeutic consistency and efficacy of CD317 MSCs through stabilizing TSG6 by PTX3.

Shi S, Chen S, Liang B, Li Y, Ma Q, Li M Stem Cell Res Ther. 2024; 15(1):92.

PMID: 38539221 PMC: 10976765. DOI: 10.1186/s13287-024-03706-3.


References
1.
Kfoury Y, Scadden D . Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell. 2015; 16(3):239-53. DOI: 10.1016/j.stem.2015.02.019. View

2.
Parazzi V, Lavazza C, Boldrin V, Montelatici E, Pallotti F, Marconi M . Extensive Characterization of Platelet Gel Releasate From Cord Blood in Regenerative Medicine. Cell Transplant. 2015; 24(12):2573-84. DOI: 10.3727/096368915X687471. View

3.
Zhou Q, Wang M, Yuan Y, Wang X, Fu R, Wan H . Complete Meiosis from Embryonic Stem Cell-Derived Germ Cells In Vitro. Cell Stem Cell. 2016; 18(3):330-40. DOI: 10.1016/j.stem.2016.01.017. View

4.
Xu J, Chen J, Li W, Lian W, Huang J, Lai B . Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus. J Am Soc Nephrol. 2019; 31(1):54-65. PMC: 6935004. DOI: 10.1681/ASN.2019050545. View

5.
Wang Y, Chen X, Cao W, Shi Y . Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014; 15(11):1009-16. DOI: 10.1038/ni.3002. View